Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NTRA 
Natera Inc (NTRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: NTRA (4-star) is a REGULAR-BUY. BUY since 39 days. Profits (0.92%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
21 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $192.78
1 Year Target Price $192.78
| 12 | Strong Buy |
| 8 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 47.82% | Avg. Invested days 38 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 21.95B USD | Price to earnings Ratio - | 1Y Target Price 192.78 |
Price to earnings Ratio - | 1Y Target Price 192.78 | ||
Volume (30-day avg) 21 | Beta 1.74 | 52 Weeks Range 92.14 - 183.00 | Updated Date 07/2/2025 |
52 Weeks Range 92.14 - 183.00 | Updated Date 07/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.46 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-06-12 | When After Market | Estimate -0.7 | Actual -0.5 |
Profitability
Profit Margin -10.36% | Operating Margin (TTM) -15.78% |
Management Effectiveness
Return on Assets (TTM) -8.87% | Return on Equity (TTM) -18.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 21148400871 | Price to Sales(TTM) 11.99 |
Enterprise Value 21148400871 | Price to Sales(TTM) 11.99 | ||
Enterprise Value to Revenue 11.55 | Enterprise Value to EBITDA -26.8 | Shares Outstanding 136547008 | Shares Floating 132177089 |
Shares Outstanding 136547008 | Shares Floating 132177089 | ||
Percent Insiders 3.25 | Percent Institutions 96.37 |
Analyst Ratings
Rating 4 | Target Price 192.78 | Buy 8 | Strong Buy 12 |
Buy 8 | Strong Buy 12 | ||
Hold - | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Natera Inc
Company Overview
History and Background
Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas. The company focuses on genetic testing and diagnostics, initially specializing in non-invasive prenatal testing (NIPT). Over time, it has expanded its portfolio to include oncology and organ health testing.
Core Business Areas
- Women's Health: Offers non-invasive prenatal testing (NIPT) like Panorama, which screens for chromosomal abnormalities in a fetus using a blood sample from the mother. It detects conditions like Down syndrome, Edwards syndrome, and Patau syndrome.
- Oncology: Provides personalized cancer testing services under the Signatera brand. This includes circulating tumor DNA (ctDNA) testing to monitor treatment response, detect minimal residual disease (MRD), and identify recurrence in cancer patients.
- Organ Health: Offers Prospera, a test used to assess organ transplant rejection risk by measuring donor-derived cell-free DNA (dd-cfDNA) in the recipient's blood. It aids in managing kidney, heart, and lung transplant patients.
Leadership and Structure
The company is led by Steve Chapman, CEO. The organizational structure consists of functional departments such as R&D, Sales and Marketing, Operations, and Finance, with a board of directors providing oversight.
Top Products and Market Share
Key Offerings
- Panorama NIPT: A non-invasive prenatal test that screens for chromosomal abnormalities. Competitors include Illumina (VeriSeq), Roche (Harmony), and PerkinElmer. Market share information varies but Natera is considered a significant player in the NIPT market. Revenue from this product is not separately disclosed.
- Prospera: A test to assess organ transplant rejection risk. CareDx is a key competitor (AlloSure). Natera does not disclose exact market share.
- Signatera ctDNA: A personalized cancer test for monitoring treatment response, detecting MRD, and identifying recurrence. Key competitors include Guardant Health (Guardant360), Exact Sciences (OncoDetect), and Roche. Natera does not disclose exact market share but is considered a key player with Signatera.
Market Dynamics
Industry Overview
The genetic testing and diagnostics industry is experiencing rapid growth, driven by advancements in technology, increasing awareness, and demand for personalized medicine. The market is highly competitive and subject to regulatory oversight.
Positioning
Natera is positioned as a leader in cell-free DNA testing, offering a comprehensive portfolio of products across women's health, oncology, and organ health. Its competitive advantages include its proprietary technology, strong brand reputation, and established relationships with healthcare providers.
Total Addressable Market (TAM)
The total addressable market for Natera's offerings is substantial, estimated in the billions of dollars across its three core areas. The company is strategically positioned to capture a significant share of this market through continued innovation and expansion of its product portfolio.
Upturn SWOT Analysis
Strengths
- Proprietary technology in cell-free DNA analysis
- Diverse product portfolio across multiple healthcare segments
- Strong brand recognition and reputation
- Established relationships with healthcare providers
- Experienced management team
Weaknesses
- High operating expenses and net losses
- Reliance on reimbursement from insurance companies
- Competition from larger, more established players
- Potential for technological obsolescence
Opportunities
- Expanding into new geographic markets
- Developing new diagnostic tests and applications
- Partnering with pharmaceutical companies
- Increasing awareness and adoption of genetic testing
- Growth in personalized medicine
Threats
- Changes in reimbursement policies
- Increasing competition
- Regulatory challenges
- Potential for patent infringement lawsuits
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- ILMN
- Caredx
- GH
Competitive Landscape
Natera's advantages include its innovative technology and diverse product portfolio. Disadvantages include its smaller size and limited financial resources compared to some competitors.
Major Acquisitions
Biotrove, Inc.
- Year: 2020
- Acquisition Price (USD millions): 41
- Strategic Rationale: Acquisition of core cell-free DNA technology patents.
Growth Trajectory and Initiatives
Historical Growth: Natera has experienced significant revenue growth in recent years, driven by increased adoption of its products and expansion into new markets.
Future Projections: Analyst estimates suggest continued revenue growth for Natera, driven by increasing demand for genetic testing and the company's strong competitive position. However, profitability remains a challenge.
Recent Initiatives: Recent initiatives include expanding the Signatera platform for cancer monitoring, developing new tests for organ health, and increasing investments in R&D and sales and marketing.
Summary
Natera has shown significant growth driven by their products in the NIPT, cancer, and organ health spaces. The company's revenue is growing as its market footprint becomes bigger. However, profitability is a problem due to the operational costs of doing business and a high amount of debt. Natera should watch out for potential competition from larger, more established companies, regulatory or reimbursement changes and patent challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Research Reports
- Market Data
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and may vary based on source and methodology.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Natera Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2015-07-02 | CEO & Director Mr. Steven Leonard Chapman | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 4424 | Website https://www.natera.com |
Full time employees 4424 | Website https://www.natera.com | ||
Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product. It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories, and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.